Stocktwits on MSN
MIRM stock clocks best day in 4.5 months on liver disease trial data: Retail eyes buyout at a premium
In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases. ・The ...
Viridian Therapeutics, Inc. VRDN shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...
The Phase 2 study is being conducted under an IND with the FDA and includes leading investigators from Vanderbilt University, ...
InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of ...
BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, reporting statistically significant phase 3 efficacy data that analysts have deemed ...
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results